Tsubota Laboratory Incorporated Financial Summary for the Second Quarter of the Fiscal Year Ending March 2027

Overview of Performance

The Company made MediProduce Co., Ltd. a consolidated subsidiary in July 2026 and has prepared consolidated interim financial statements from this interim period. For the interim period of the fiscal year ending March 2027, consolidated net sales were 491,981 thousand yen, operating loss was 331,127 thousand yen, ordinary loss was 294,611 thousand yen, and net loss attributable to owners of parent was 295,444 thousand yen. Sales increased due to contributions from the newly consolidated subsidiary; however, expenses such as research and development and promotional costs were heavy, resulting in a recorded deficit. The full-year earnings forecast has been revised and published, and continued promotion of licensing and new out-licensing agreements will be important.

Business Strategy and Capital Policy Trends

The Company reorganized into three segments: R&D, PCO, and HC. Approximately 1,990 million yen was raised through a third-party allotment of stock acquisition rights, planned to be allocated to clinical development, out-licensing investments, and the ReLight Tech business. Through the consolidation of MediProduce, the Company aims to diversify its revenue base and strengthen the funding base for growth investments.